First-in-Human Study of ATX-559, an Oral Inhibitor of DHX9, in Patients With Advanced or Metastatic Solid Tumors, and Molecularly Defined Cancers
Accent Therapeutics
Accent Therapeutics
Mirati Therapeutics Inc.
Baylor Research Institute
Pheon Therapeutics
Novartis
Takeda
Tempus AI
NuCana plc
Institut Bergonié
Eli Lilly and Company
Swiss Cancer Institute
Mirati Therapeutics Inc.
University of Iowa
Washington University School of Medicine
Peter MacCallum Cancer Centre, Australia
Mayo Clinic
Alliance for Clinical Trials in Oncology
Mirati Therapeutics Inc.
NantCell, Inc.
NextCure, Inc.
Columbia University
Ohio State University Comprehensive Cancer Center
ADC Therapeutics S.A.
Columbia University
Milton S. Hershey Medical Center
HiberCell, Inc.
Gilead Sciences
Stanford University
pharmaand GmbH
NSABP Foundation Inc
Roswell Park Cancer Institute
Eastern Cooperative Oncology Group
Eisai Inc.
Masonic Cancer Center, University of Minnesota
Northwell Health
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Imunon
Royal Marsden NHS Foundation Trust
Icahn School of Medicine at Mount Sinai
Washington University School of Medicine
Hadassah Medical Organization
Sun Yat-sen University
Assistance Publique - Hôpitaux de Paris
EndoVigilant Inc
MacroGenics
Fox Chase Cancer Center
Gradalis, Inc.
NSABP Foundation Inc
University Health Network, Toronto
Gilead Sciences